PT-141 (Bremelanotide)
PH-PT141-001
Specifications
Description
PT-141 (Bremelanotide) is a synthetic peptide melanocortin receptor agonist FDA-approved for hypoactive sexual desire disorder. This cyclic heptapeptide acts centrally to enhance sexual arousal.
Mechanism of Action
PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system to enhance sexual desire and arousal. FDA approved in 2019 for premenopausal women with hypoactive sexual desire disorder (Dhillon & Keam, 2019).
Research Applications
- Sexual dysfunction research (Dhillon & Keam, 2019)
- Melanocortin receptor studies (Hedlund, 2004)
- Central nervous system effects
- Arousal mechanism research
Product Specifications
- Purity: ≥99% (HPLC verified)
- Molecular Weight: 1025.2 Da
- Form: Lyophilized powder
- Storage: -20°C
References
- Dhillon S, Keam SJ. Drugs. 2019. PMID: 31429064
- Hedlund P. Curr Opin Investig Drugs. 2004. PMID: 15134289
Documentation
Storage and Handling
- ❄️ Store lyophilized peptide at -20°C or below
- 🔒 Protect from light and moisture
- 🌡️ Allow vial to reach room temperature before opening
- 💧 Reconstitute with appropriate sterile solvent
- 📦 Aliquot to avoid repeated freeze-thaw cycles
Research Overview
PT-141 (Bremelanotide) is a synthetic peptide compound used in laboratory research settings. Researchers studying melanocortin receptor system research use this compound to investigate cellular signaling pathways, receptor binding affinities, and structure-activity relationships. Each batch is manufactured under controlled conditions and verified through HPLC and mass spectrometry analysis to ensure consistency across experimental replicates.
Documentation & Resources
- Certificate of Analysis for PT-141 (Bremelanotide) — batch-specific purity and identity verification
- Research Blog — protocols, guides, and peptide research literature
- Research Use Policy — handling and compliance guidelines
